FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * LEVIN ARTHUR A 2. Issuer Name and Ticker or Trading Symbol Avidity Biosciences, Inc. [ RNA ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Scientific Officer
(Last)         (First)         (Middle)
C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150
3. Date of Earliest Transaction (MM/DD/YYYY)
6/24/2021
(Street)
LA JOLLA, CA 92037
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  6/24/2021    M(1)    100  A $1.24  1430  D   
Common Stock  6/24/2021    S(1)    100  D $27.755  1330  D   
Common Stock  6/25/2021    M(1)    17017  A $1.24  18347  D   
Common Stock  6/25/2021    M(1)    3083  A $0.53  21430  D   
Common Stock  6/25/2021    S(1)    17453  D $27.9703 (2) 3977  D   
Common Stock  6/25/2021    S(1)    2647  D $29.1398 (3) 1330  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $1.24  6/24/2021    M (1)       100    (4) 2/18/2030  Common Stock  100  $0.00  208183  D   
Stock Option (Right to Buy)  $1.24  6/25/2021    M (1)       17017    (4) 2/18/2030  Common Stock  17017  $0.00  191166  D   
Stock Option (Right to Buy)  $0.53  6/25/2021    M (1)       3083    (5) 8/27/2027  Common Stock  3083  $0.00  42347  D   

Explanation of Responses:
(1)  The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
(2)  The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.80 to $28.71. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(3)  The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.22. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(4)  25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.
(5)  This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
LEVIN ARTHUR A
C/O AVIDITY BIOSCIENCES, INC.
10975 N. TORREY PINES RD., SUITE 150
LA JOLLA, CA 92037


Chief Scientific Officer

Signatures
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact 6/28/2021
**Signature of Reporting Person Date
Avidity Biosciences (NASDAQ:RNA)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Avidity Biosciences Charts.
Avidity Biosciences (NASDAQ:RNA)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Avidity Biosciences Charts.